Business
Launch of LPLDL® product with AlfaSigma
Launch of LPLDL® product with AlfaSigma.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \nRNS Number : 9196A OptiBiotix Health PLC 27 January 2020 \n\n27 January 2020\n \nOptiBiotix Health plc\n(\"OptiBiotix\" or the \"Company\")\n \nLaunch of LPLDL® product with AlfaSigma\n \nProBiotix Health, a fully-owned subsidiary of OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, communicate that ALFASIGMA S.p.A. (\"ALFASIGMA\") has recently announced the launch of a food supplement containing the cholesterol reducing LPLDL® probiotic strain developed by ProBiotix Health. ALFASIGMA will market this first of its kind nutraceutical probiotic in Italy for cholesterol reduction. This agreement follows on from the announcement (RNS: 21 June 2018) that OptiBiotix had entered into license agreement with \"ALFASIGMA\" to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain in Italy.\n \nALFASIGMA, is a multinational pharmaceutical company with 2018 revenues in excess of €1 billion and around 3000 employees globally. Whilst Italy is its core market, ALFASIGMA is present in more than 90 countries through distributors and subsidiaries. \n \nThe launch is being supported by an extensive marketing campaign aimed at General Practitioners, cardiologist, and pharmacists, to promote treatment of at risk patients using a natural, scientifically formulated, food supplement. Italy is the largest probiotic supplement market in Europe, and the second largest market in the world, with an estimated >$500 million probiotic supplements market, and a 25% per annum growth forecast to 2021*.\n \n*Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017). \n \nStephen Prescott, Chief Executive of ProBiotix Health, commented: \"We are pleased to communicate the launch of a new product developed by one of the largest pharmaceutical companies in Italy and containing our cholesterol reducing probiotic, LPLDL®. Italy is the largest and fastest growing probiotic market in Europe and we are pleased to partner with a company with such a strong track record in food supplements and pharmaceuticals for cardiovascular health. The launch of this product is another step in e...